In the fight against the deadliest drug crisis in American history, one of the most promising weapons is a converted bus parked on a main road in Woonsocket, Rhode Island. A new study published in Addiction Science & Clinical Practice offers the most detailed look yet at how a mobile health unit delivering medications for opioid use disorder has functioned on the ground—documenting both its life-saving reach and the stubborn structural obstacles that threaten its survival.

The research, led by Augustine Kang of Boston Children’s Hospital and Amelia Bailey of the Brown University School of Public Health, together with colleagues at CODAC Behavioral Healthcare and the University of Massachusetts Chan Medical School, examined the implementation and impact of a mobile unit launched in July 2022 by CODAC, Rhode Island’s largest provider of opioid treatment services. The unit operates in two capacities: as a fully licensed opioid treatment program that prescribes and dispenses medications six days a week in Woonsocket—a city with one of the highest per capita overdose rates in the state—and as a community outreach service providing harm reduction supplies, counseling, and linkages to care in under-resourced areas.

To understand how the unit works in practice, the research team conducted semi-structured qualitative interviews with 15 stakeholders between August and November 2024. Participants included mobile unit staff and clinicians, staff from CODAC’s brick-and-mortar clinics, organizational leadership, community partners, and a representative of the State Opioid Treatment Authority. Interviews, which averaged 54 minutes, were analyzed using a template thematic approach organized around the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework, supplemented by principles from the Health Equity Implementation Framework. The researchers reached thematic saturation after 12 interviews and used NVivo software to code and organize the data.

The picture that emerged is one of an intervention that is simultaneously indispensable and precarious. Stakeholders overwhelmingly endorsed the mobile unit as a critical tool for reaching people whom the traditional treatment system has failed: people experiencing homelessness, economic instability, and the transportation barriers that make daily visits to a fixed clinic nearly impossible. Because federal regulations require in-person contact to initiate methadone treatment, participants explained, people who are unhoused or transient often cannot access care at all. The mobile unit dissolves that barrier by bringing dosing, assessment, and intake directly into the neighborhoods where patients live.

The unit’s value extends well beyond medication itself. Participants described how the unit functions as a comprehensive health hub—offering blood pressure checks, wound care, harm reduction supplies such as clean needle and wound kits, and referrals to primary care for unmanaged chronic conditions like hypertension and diabetes. Staff noted that many patients arrive with years of neglected medical needs, and the mobile unit serves as a re-entry point into the broader health system. This integrated model, the authors note, aligns with research showing that combining medications for opioid use disorder with primary care improves retention in treatment and overall health outcomes.

Perhaps the most striking finding concerns the quality of relationships the unit fosters. Unlike conventional clinics, where patients described a culture of arriving, dosing, and leaving, the mobile unit’s compact environment allows staff to know patients by name and build therapeutic rapport more quickly. Participants credited this familiarity with keeping people engaged in care even during periods of active substance use, describing a welcoming, nonjudgmental “family-oriented environment.” Practical incentives also mattered: early monetary incentives in the form of small gift cards drew patients in, but over time, staff reported, external motivation gave way to intrinsic motivation. The ability to earn take-home doses of methadone emerged as one of the strongest retention tools, giving patients a tangible goal and a growing sense of autonomy.

Stakeholders also described how the medications themselves transform lives. Participants with years of clinical experience described patients regaining “breathing room”—freedom from the daily cycle of withdrawal and drug-seeking that allowed them to rebuild families, secure employment, and escape legal entanglements. Several recounted patients bringing parents, children, and partners into treatment, breaking cycles of generational addiction. One staff member of 14 years described watching people go from rock bottom to full-time jobs and stable family lives.

Yet the study is equally candid about the forces working against the unit. Staffing shortages loomed over nearly every conversation: the unit is not fully staffed, and counseling and case management services are provided by staff rotated in from Providence rather than a dedicated mobile team. Low insurance reimbursement rates and the precarious nature of grant funding left participants worried about long-term sustainability. The physical constraints of the vehicle itself—only one enclosed office space for private conversations, with counseling elsewhere conducted behind dividers and sound machines—require a specific kind of professional who thrives on outreach work. Weather posed its own hazards: after patients were found waiting in freezing snow, the unit changed its policy to provide take-home doses whenever snow was forecast.

External resistance proved equally formidable. Stakeholders described political opposition from municipal officials who attempted to use zoning ordinances to shut down services in one community, requiring legal intervention to resolve. Law enforcement activity near treatment sites—such as traffic stops targeting patients arriving for care—forced some patients to weigh the risk of arrest against their need for medication. Remarkably, however, the study also documents a counter-trend: through proactive engagement and education, staff built relationships with police departments, and in some cases officers began referring individuals to the unit instead of arresting them. Over time, sustained operation also softened community stigma, as residents observed that the unit did not produce the negative consequences they had feared.

The authors are careful to note a key limitation: no patients were interviewed directly, so all findings about patient experiences reflect staff and stakeholder perceptions rather than patients’ own voices. Even so, the implications are clear. The number of federally approved methadone mobile units in the United States has grown from just 8 in 2022 to 64 by early 2025, following the reversal of a Drug Enforcement Administration moratorium that had blocked expansion since 2007. Yet a recent scoping review cited in the study found that such units remain under-utilized, suggesting both unmet need and unrealized potential.

The stakeholders in this study offered a roadmap for realizing that potential: better marketing and outreach, including social media presence; large-scale de-stigmatization campaigns framed around the simple logic that addiction should be treated like any other medical condition; expanded staffing, including additional nurses and providers; improved language access for non-English speakers; stronger partnerships with housing services and food pantries; and, above all, stable long-term funding. Some participants also envisioned expanded services such as community drug-checking for polysubstance users—a ground-level harm reduction tool suited to the modern, fentanyl-saturated drug supply.

What the study ultimately documents is a model of care that works—not in the abstract, but in the specific, textured reality of snowy parking lots, gift card incentives, police negotiations, and patients who show up even at their lowest points. The unit’s flexibility is itself a structural advantage: unlike a fixed clinic, a bus can move if a neighborhood objects. As one participant put it, “the bus makes it a little bit less scary.” Whether these lifelines on wheels become a permanent fixture of the American addiction treatment landscape will depend less on clinical evidence—which increasingly supports them—than on the funding streams, policies, and political will required to keep the engines running.